X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-20

Reporting Person: Section 32 Fund 1, LP (10% Owner)
Reporting Person: Section 32 GP 1, LLC (10% Owner)
Reporting Person: Maris William J (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-20	Common Stock	C	451362	—	Acquired	451362	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-20	Series D Convertible Preferred Stock	$	C	1540500	Disposed		Common Stock (451362)	Direct

Footnotes

F1: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F2: The reported securities are held of record by Section 32 Fund 1, LP ("Fund 1"). Section 32 GP 1, LLC (the "GP"), the general partner of Fund 1, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 1. Such persons and entities disclaim beneficial ownership of shares held by Fund 1 except to the extent of any pecuniary interest therein.